18 Dengue virus (DENV), an arthropod-borne ("arbovirus") virus causing a range of 19 human maladies ranging from self-limiting dengue fever to the life-threatening 20 dengue shock syndrome, proliferates well in two different taxa of the Animal 21 Kingdom, mosquitoes and primates. Unexpectedly, mosquitoes and primates have 22 distinct preferences when expressing their genes by translation, e.g. members of 23 these taxa show taxonomic group-specific intolerance to certain codon pairs. This is 24 called "codon pair bias". By necessity, arboviruses evolved to delicately balance this 25 fundamental difference in their ORFs. Using the mosquito-borne human pathogen 26 DENV we have undone the evolutionarily conserved genomic balance in its ORF 27 sequence and specifically shifted the encoding preference away from primates. 28 However, this recoding of DENV raised concerns of 'gain-of-function,' namely 29 whether recoding could inadvertently increase fitness for replication in the 30 arthropod vector. Using mosquito cell cultures and two strains of Aedes aegypti we 31 did not observe any increase in fitness in DENV2 variants codon pair deoptimized 2 32 for humans. This ability to disrupt and control an arbovirus's host preference has 33 great promise towards developing the next generation of synthetic vaccines not only 34 for DENV but for other emerging arboviral pathogens such as chikungunya virus 35 and Zika virus. 36 37 Introduction 38 Synthetic biology has the potential to revolutionize the rapid development of 39 vaccines to treat infectious diseases as the research paradigm shifts from empirical 40 to rational design [1,2]. Since the first demonstration of an infectious fully synthetic 41 virus in 2002 (7.5 kb) [3] and the ensuing initial societal concerns[4], rapid 42 advances in DNA synthesis including decreased cost [5], has led to the general 43 acceptance of synthetic organisms as a research tool[1,6,7]. This has also resulted in 44 the rapid development of a new generation of synthetic vaccine candidates 45 beneficial for humans and domesticated animals[1]. The conception of novel 46 beneficial variants of existing organisms for the treatment of cancer[8,9] or for use 47 as vaccines[10,11] have become new exciting branches in molecular medical 48 research. However, there have been apprehensions over the use of this technology 49 to synthesize dangerous pathogens by chemical synthesis such as poliovirus [4] or 50 1918 Influenza virus [12]. Alarm has been expressed about the ethics of using this 51 technology: while there is great promise for the production of novel vaccines to 52 improve human health there are also risks if the technology is misused, a dilemma 53 referred to as "Dual Use Research"[13]. 54 DENV is an enveloped, plus stranded RNA arbovirus (genome ~11 kb) of the 55 genus Flavivirus, family Flaviviridae. DENV is separated into 4 serotypes and is 56 primarily transmitted by the urban-adapted Aedes aegypti mosquito, a vector that 57 has become widely distributed in tropical and subtropical regions. Efforts leading to 58 an effective DENV vaccine have been complicated by the requirement that it must be 59 tetravalent. Vaccination with a tetravalent vaccine can fortuitously lead to 60 preferential protection against one serotype Iffollowed by infection with a another 61 single serotype, this may lead to severe or lethal disease mediated by antibody-62 dependent enhancement [14]. Complications with tetravalent DENV vaccines that 3 63 have been recently reported call for new approaches to avoid unwanted outcomes 64 [15,16]. Here we report further characterization of the first synthetic wild-type 65 DENV2 based on strain 16681[17], and several in silico designed attenuated DENV2 66 variants carrying large-scale, but selective, genomic recoding of the open reading 67 frame (ORF). 68 There are multiple methods of recoding a viral genome to achieve attenuation 69 including the introduction of random point mutations [18], scrambling of codons 70 while maintaining natural biases [19], reduction of codon bias for the host organism
94 Aedes genome [17] . 95 Codon pair deoptimization (CPD) describes our method to introduce into a 96 reading frame of the DENV coding sequence a large number of synonymous, 97 disfavored (bad) codon pairs with negative codon pair scores without introducing 98 mutations in the polyprotein or changing the use of existing codons. We note that 99 the biological difference between "good" and "bad" codon pairs is small. However, if 100 a large number of "bad" codon pairs are introduced into the ORF, the effect is 101 disastrous for viral gene expression [21] . Our recoding strategy has raised a concern 102 that dramatic recoding of the DENV genome may have unforeseen and dangerous 103 consequences vis a vis the invertebrate vector. Whether through interaction 104 between the RNAi based immune system of the mosquito [30] or some other means 105 yet unidentified, there is a possibility that a sequence unknown to nature could have 106 advantages that would enhance infection . We have, therefore, studied DENV 107 variants for increased replication in mosquito cells. No apparent "gain-of-function" 108 of these engineered strains was observed in vitro or in vivo using two different 109 strains of Ae. aegypti.
110
111 Results
112
Synthesis and analysis of synthetic dengue type 2 infectious cDNA (DENV2 syn ) 113 Following in silico design, we synthesized three live-attenuated DENV2 viruses, 114 each individually with human codon pair deoptimized coding sequences in one 115 specific coding region of the polyprotein, yet leaving the insect-specific codon pair 116 bias nearly wild type ( Fig. 1) . We refer to these DENV variants as E hmin , NS3 hmin , and We further tested viral replication in mosquitoes by using both intrathoracic 216 injection (to bypass the midgut infection and replication barriers) as well as 217 infectious bloodmeal (to measure viral replication under more natural conditions).
218 Adult Ae. aegypti were intracranially injected with 2 x 10 4 FFU virus. Mosquitoes 219 were collected on days 3, 6, 9, and 12 p.i. and analyzed by Taqman RT-PCR to see if 220 there were any differences in total viral RNA titer. Among infected mosquitoes, the 221 mean viral RNA titers were statistically similar at 3, 6, 9, and 12 days post infection 222 with significantly but slightly reduced titers on days 3 (E hmin ) and 12 (E hmin , NS3 hmin ) 223 post-inoculation ( Fig. 4) . Ae. aegypti were then fed infectious bloodmeals containing 224~4.0 x 10 6 FFU/mL and tested for infection by Taqman RT-PCR. The rates of 225 infection were low, but similar for each deoptimized virus compared to wild-type 226 (Table 3) . 
254
Briefly, DENV2 syn , E hmin , or NS3 hmin were used to infect Vero cells at a 255 multiplicity-of-infection (MOI) of 0.01 at 32°C, 37°C, or 39°C (Fig. 5 ). Infected cells 256 were incubated at the respective temperature and samples were taken daily for 6 257 days-post-infection (DPI). DENV2 syn replication was not affected by incubation at 258 32°C or 37°C (Fig. 5A) , however, at 39°C a 2 log 10 FFU/mL drop ( Fig. 5B ) in 259 maximum titer was observed. In E hmin infected cells, infectious virus was recovered 260 at all three temperatures ( Fig. 3A ) but there was a 2-3 log 10 FFU/mL drop between 261 32°C and 37°C and an even greater drop of nearly 4 log 10 maximum titer (6 dpi) was 262 observed between 32°C and 39°C (Fig. 3B ). Infection of Vero cells with NS3 hmin 263 revealed a similar trend in growth kinetics with reductions in maximum titer like 264 those observed for E hmin (Fig. 5 
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The mechanism of attenuation by codon-pair deoptimization is under 311 investigation by our lab and others but remains to be solved. We suggest that it is 312 likely the result of multiple factors; these include one or several parameters of the 
